Market Closed - Nasdaq 16:00:00 2024-06-25 EDT 5-day change 1st Jan Change
0.6493 USD -51.54% Intraday chart for Beyond Air, Inc. -48.47% -66.87%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Piper Sandler Cuts Price Target on Beyond Air to $3.50 From $7, Maintains Overweight Rating MT
BTIG Downgrades Beyond Air to Neutral From Buy MT
Beyond Air Share Plunge After Fiscal Q4 Loss Exceeds Estimates MT
Beyond Air, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Transcript : Beyond Air, Inc., Q4 2024 Earnings Call, Jun 24, 2024
Beyond Air, Inc. Updates Revenue Guidance for the Fiscal Year 2025 CI
Certain Wwarrants of Beyond Air, Inc. are subject to a Lock-Up Agreement Ending on 20-JUN-2024. CI
Certain Restricted Stock Units of Beyond Air, Inc. are subject to a Lock-Up Agreement Ending on 20-JUN-2024. CI
Certain Stock Options of Beyond Air, Inc. are subject to a Lock-Up Agreement Ending on 20-JUN-2024. CI
Certain Common Stock of Beyond Air, Inc. are subject to a Lock-Up Agreement Ending on 20-JUN-2024. CI
Beyond Air Names Chief Commercial Officer MT
Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024 CI
Truist Lowers Price Target on Beyond Air to $8 From $10, Keeps Buy Rating MT
Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Beyond Air, Inc. Provides Revenue Guidance for the Fiscal Year 2025 CI
Transcript : Beyond Air, Inc., Q3 2024 Earnings Call, Feb 12, 2024
Earnings Flash (XAIR) BEYOND AIR Posts Q3 Revenue $391,000, vs. Street Est of $0.45M MT
North American Morning Briefing : Stock Futures Steady as Traders Await CPI Data DJ
Beyond Air Affiliate Says First Group Cleared in Phase 1 UNO Study in Solid Tumors; Shares Rise MT
Beyond Air Insider Bought Shares Worth $1,962,000, According to a Recent SEC Filing MT
Truist Cuts Beyond Air's Price Target to $10 From $14, Maintains Buy Rating MT
Beyond Air, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Chart Beyond Air, Inc.
More charts
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company’s areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.6493 USD
Average target price
5.875 USD
Spread / Average Target
+804.82%
Consensus
  1. Stock Market
  2. Equities
  3. XAIR Stock
  4. News Beyond Air, Inc.
  5. Earnings Flash (XAIR) BEYOND AIR Posts Q1 Revenue $59,000, vs. Street Est of $0.34M